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Asthma is a chronic inflammatory airway disease involving complex interplay between resident
and infiltrative cells, which in turn are regulated by a wide range of host mediators. Identifying
useful biomarkers correlating with clinical symptoms and degree of airway obstruction remain
important to effective future asthma treatments. Transforming growth factor b (TGF-b) is a
major mediator involved in pro-inflammatory responses and fibrotic tissue remodeling within
the asthmatic lung. Its role however, as a therapeutic target remains controversial. The aim
of this review is to highlight its role in severe asthma including interactions with adaptive T-
helper cells, cytokines and differentiation through regulatory T-cells. Associations between
TGF-b and eosinophils will be addressed and the effects of genetic polymorphisms of the
TGF-b1 gene explored in the context of asthma. We highlight TGF-b1 as a potential future ther-
apeutic target in severe asthma including its importance in identifying emerging clinical phe-
notypes in asthmatic subjects who may be suitable for individualized therapy through TGF-b
modulation.
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Asthma is a complex chronic inflammatory lung disease
where eosinophils, T-lymphocytes, macrophages, mast
cells, neutrophils and epithelial cells play key roles in
releasing cellular mediators including cytokines, chemo-
kines and growth factors that all influence disease. Inhaled
allergens sensitize dendritic cells to stimulate the prolif-
eration of T helper type 2 (Th2) cells and subsequent
release of cytokines that include interleukin IL-4, IL-5 and
IL-13 [1]. Sensitized epithelial cells also release profibrotic
mediators that include transforming growth factor-b (TGF-
b), fibroblast growth factor (Fgf) and endothelin, stimu-
lating fibroblasts and myofibroblasts to release collagen,
proteoglycan, and glycoproteins that induce airway thick-
ening [2]. These mediators control the chronic inflamma-
tion observed that induces bronchoconstriction and airway
remodeling with subsequent structural airway changes.
Allergic asthma, representing a subset of asthmatics is
characterized by chronic mucosal Th2 dominated
inflammation.
TGF-b plays a central role in the complex relationship
between the propagation of the inflammatory cascade
within the airway and association with suppressor T cell
immune function. This review aims to highlight the evi-
dence for the role of TGF-b in severe asthma which while
contributing to disease pathogenesis remains less well-
studied. Its role in the asthmatic airway has been
controversial likely because of its complex signaling
pathways and immune interactions that influence several
differing asthma phenotypes. As both airway remodelinge 1 Demographics, clinical characteristics and biomarker su
ma identified using unsupervised hierarchical cluster analy
acic Society definition of severe asthma and correlate with ph
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onset asthmaand poor treatment response are significant in severe
asthma, it would appear logical that TGF-b would be
relevant in this context and warrants review [3]. Severe
asthma is a spectrum of disease with significant morbidity
and mortality [4]. The National Heart, Lung, and Blood
Institute (NHLBI) Severe Asthma Research Program iden-
tifies five clusters of phenotypically distinct individuals
with severe asthma by performing cluster analysis. The
groups range from early onset atopic asthma with normal
lung function to subjects with severe airflow obstruction
(Table 1) [5].
Airway remodeling in asthma constitutes subepithelial
fibrosis, deposition of extracellular matrix protein, goblet
cell hyperplasia, mucus gland and smooth muscle hyper-
trophy, and epithelial damage [6e8]. Inflammatory path-
ways regulate all such features [8]. Several key mediators
including TGF-b, vascular endothelial growth factor (VEGF),
ADAM metallopeptidase domain 33 (ADAM-33), matrix
metalloproteinase-9 (MMP-9) and the Th2 cytokine family
including IL-5, 13 and 14 have been identified.
TGF-b has been a focal point of considerable investiga-
tion as both a mediator and effector molecule in the Th2
driven immune cascade. Produced by numerous cell types
including epithelial cells, eosinophils, macrophages, and
fibroblasts, it is involved in epithelial transformation, sub-
epithelial fibrosis, airway smooth muscle (ASM) remodeling,
microvascular changes, and mucus production. Insight into
mechanisms of TGF-b signaling provides key information
into the crosstalk between activation pathways, T-regula-
tory (Treg) signaling, and immune cell interactions hence
its importance in the context of asthma.bsets classified by cluster analysis. Five clinical phenotypes of
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cesses occurring in idiopathic pulmonary fibrosis and pul-
monary arterial hypertension [9]. These include barrier
dysfunction, smooth muscle proliferation and accumulation
of lamina reticularis, myofibroblasts and smooth muscle
cells that lead to fibrotic airway remodeling [10,11].
Characterization of pathophysiologic sub-phenotypes of
severe refractory asthma is beneficial in expanding our
understanding of the underlying biologic factors that are
potentially ‘druggable’ therapeutic targets. For instance,
sputum eosinophilia identified by cluster analysis is char-
acteristic of later onset asthma (>12 years), severe eosin-
ophilic inflammation and association with nasal polyposis
and rhinosinusitis [12e15]. Targeting eosinophilia with the
IL-4-blocker dupilumab has demonstrated fewer asthma
exacerbations and a reduced level of Th2-associated in-
flammatory markers [16]. Treatment of severe refractory
asthma remains a key clinical challenge and is associated
with a high and disproportionate consumption of healthcare
resources. Therefore, emerging avenues to improve un-
derstanding and therapy is critical for progress in the field
[12,17].
Transforming growth factor beta (TGF-ß)
The TGF-ß superfamily of ligands are multifunctional reg-
ulators implicated in various biological processes within the
airways including alveolarization, epithelial and endothe-
lial barrier function, immune cell recruitment, platelet
aggregation, apoptosis, cell differentiation and prolifera-
tion [18]. These regulators consist of more than 33 mem-
bers including TGF-ß, bone morphogenetic proteins (BMP),Figure 1 TGF-b1 activation. Activation of TGF-ß1 receptors leads
Smad proteins [2] that act as transcription factors to regulate gene
translocate into the nucleus [4]. In a negative feedback loop, inhibit
to the type I receptor.[5].growth and differentiation factors (GDFs), activins and in-
hibins. This super-family in humans demonstrates three
mammalian isoforms (TGF-ß1, 2 and 3) that share 60e80%
homology.
TGF-b isoforms have a number of specific and shared
roles in the regulation of airway inflammation and the
remodeling process [19]. The three isoforms described each
have important roles in the regulation of inflammation, cell
growth and differentiation [20]. TGF-b bound to latency-
associated peptide (LAP) is inactive and therefore under-
standing its regulation is pivotal to appreciating functional
consequences [21,22]. Although each isoform is encoded by
differing genes, important properties are shared such as
common cell surface receptors and cellular targets [23].
The expression of TGFb-1 is altered in the asthmatic
airway and current evidence suggests this is the case for
both human and animal settings. Known as the ubiquitous
prototype of this family, TGF-b1 is most prevalent in
mammalian tissues [24]. Produced as an inactive latent
complex made up of LAP and latent TGF-ß-binding protein
(LTBP), it is targeted to the extracellular matrix (ECM) [25].
Maturation of inactive complexes depends on dissociation
of covalent bonds that in turn rely on pH changes enabling
binding to cell surface receptors. TGF-ß1 activation how-
ever requires further binding of a(v) integrin to a sequence
in its pro-domain [23]. Its ability to recruit single trans-
membrane subunits into a hetero-oligomer enables TGF-ß1
to form a functional receptor (Fig. 1). TGF-ß1 signal
transduction occurs through Smad-dependent or indepen-
dent pathways [26]. TGF-ß1 type I and II receptors both
transmembrane serine/threonine kinases (e.g. activin
receptor-like kinase 5 (ALK5)) stimulate a cascade of intra-to dimerization [1] and phosphorylation of receptor-activated
expression. Smad 2 and 3 form complexes with Smad 4 [3] that
ory Smad 7 induced by Smad 3 blocks TGF-ß signaling by binding
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signaling, and are surrogates to assess levels of pathway
activity. Activated TGF-ß1 receptors lead to phosphoryla-
tion of Smad proteins that in turn are transcription factors
regulating gene expression. Smads 2 and 3 form complexes
with Co-Smad (Smad 4) and translocate into the nucleus. In
a negative feedback loop, inhibitory Smad (Smad 7) induced
by Smad 3 blocks TGF-ß signaling by type I receptor binding
(Fig. 1). Increased TGF-ß1 signaling as evidenced by
increased phospho-Smad 2 levels, have been reported in
the bronchial biopsies of asthmatic subjects [27]. Smad 3
signaling however is required for the recognized allergen-
induced airway remodeling and myofibroblast accumula-
tion [28]. TGF-ß1 also activates Smad independent path-
ways such as the mitogen-activated protein kinase (MAPK)
pathways: extra cellular signal-regulated kinase (ERK), p38
MAPK and c-Jun-N-terminal kinase (JNK) [29e31].
TGF-b2 isoforms are expressed by eosinophils and are
the predominant form in severe allergic asthma where it
promotes profibrotic responses affecting airway remodeling
in addition to regulating mucin production and impacting on
non-asthma related atopy in children [32e35]. Interest-
ingly, TGF-b3 is implicated in the development of a severe
phenotype of chronic airway remodeling induced by house
dust mite (HDM) [35]. In this setting, increased mucus
production, collagen deposition, and a dysregulated cyto-
kine environment are observed. Our understanding of iso-
form specific effects of TGF-b in the context of asthma is
only in its infancy and will need to be considered in future
treatment studies.
While TGF-ß is secreted by almost all immune cells
including fibroblasts, endothelial cells and vascular/ASM
cells [36e39], airway epithelia remain the major site of
TGF-ß1 expression. In asthmatic airways however, TGF-ß
expression is markedly increased and further augmented by
the infiltrative inflammatory groups of cells that serve as an
additional reservoir. An example of this is active eosinophil
recruitment by chemokine ligand 5 (CCL-5) and CCL-11 that
account for 80% of TGF-b expression in asthma [40e42]. A
reduced deposition of the TGF-ß binding proteoglycan
decorin within the asthmatic airway wall further increases
its bioavailability in this context [16]. Owing to its abun-
dance in the asthmatic airway and its complex but well
understood signaling mechanisms, it appears logical that
therapies directed at TGF-ß1 be considered in the context
of severe refractory asthma.TGF-ß airway remodeling
Airway remodeling is the pathophysiologic modification of
normal airway wall structure comprising a complex re-
organization of the wall’s molecular and cellular constitu-
ents [43]. Including a repair process in response to airway
wall injury, the dysregulated ensuing inflammation leads to
structural change that results in loss of epithelial integrity,
basement membrane thickening, subepithelial fibrosis,
mucus gland and goblet-cell hyperplasia, smooth muscle
hypertrophy and increased airway vascularity [44e46].
Fibrosis is the end-point of such a process within the ECM
that also affects other organs including the liver and kid-
ney. During its induction, TGF-ß1 promotes target genesincluding connective tissue growth factor (CTGF), a-smooth
muscle actin, collagen and plasminogen activator inhibitor
[43,47]. In mild-to-moderate asthma, such modifications
are partially reversible, however in severe chronic asthma,
this becomes irreversible. Studies show that airway
remodeling is primarily responsible for symptoms associ-
ated with decreased pulmonary function [48].
In the context of asthma, TGF-ß induce both anti- and
pro-apoptotic effects in airway epithelial cells [47]. Anti-
apoptotic effects are mediated through the SMAD 2/3
pathway and occur in the absence of chemical or physical
stress. Chronic allergenic exposure allows TGF-ß1 to induce
apoptosis through activation of MAPK-signaling [49]. Injury
to surface epithelia follow aggravated by a dysregulated
repair process causing detachment of these cells and epi-
thelialemesenchymal transition (EMT) [50].
TGF-ß1 also affects sub-epithelial fibrosis by increasing
deposition of ECM such as type I and III collagen, fibronectin
and proteoglycans. By inducing fibroblastic differentiation
to myofibroblasts, increased proliferation follows [51,52].
Fibroblasts maintain crucial roles during the pulmonary
fibrotic response which are dependent on activation of
TGF-ß1 via ECM receptor integrins [53,54]. Additionally,
TGF-ß1 induces myofibroblast differentiation and collagen
production in nasal polyposis re-iterating its important role
in airway disease [55].
Matrix metalloproteinases (MMPs) are key enzymes
responsible for ECM remodeling, cell migration, and airway
epithelial repair [56]. Cytokines including TGF-b1 play
pivotal roles in MMP-9 production and secretion [57]. The
quantity of submucosal neutrophils and macrophages, but
not eosinophils, is significantly higher in asthmatics and in
addition MMP-9 staining of the subepithelial basement
membrane detected [58]. Neutrophils from allergic asth-
matics produce and release MMP-9 upon direct allergen
exposure [59]. In tandem with up-regulation of TGF-b1 gene
expression by neutrophil elastase (NE) [39], activated
neutrophils release reactive oxygen species (ROS) that
exacerbate the airway remodeling process by promoting
goblet cell hyperplasia [60].
As described previously, TGF-ß is rendered latent, by
binding to LAP, which is in turn is covalently bound to a
fibrillin protein LTBP. Inflammatory ECM degradation re-
leases latent TGF-beLAP complexes that dissociate and
increase active TGF-b bioavailability within the airway [61].
LAP complexes also act as substrates for MMP-2, 9, 13 and
14 [61]. MMPs alter transcription of ECM proteins
responsible for collagen fibril laydown [62,63], and function
as proteases that lyse ECM components with release of
bioactive byproducts. In turn pro-inflammatory IL-13 stim-
ulates collagen type I production by airway fibroblasts in an
MMP and TGF-b1 dependent manner in asthma [64].
TGF-b also stimulates IL-6 which acts on ASM cells to
induce release of eotaxin and VEGF concurrently mediating
smooth muscle driven mast cell activation [65e67]. Despite
our depth of knowledge of epithelial repair mechanisms,
key questions relating to how activated cells organize into a
matrix that functions as a regulator of the repair process
still remain unanswered [56].
By far, the most crucial advance of our understanding of
TGF-ß1 function within the airway is its regulatory role in
EMT. Pulmonary alveolar epithelium, primary human
Transforming growth factor beta in severe asthma 1413bronchial epithelia and airway epithelial cells isolated from
asthmatic lungs have all demonstrated the ability to un-
dergo EMT upon TGF-ß1 stimulation. This process can be
inhibited with use of TGF-ß1 inhibitors such as Smad 7
[68,69]. In addition, TGF-ß1 influences EMT degradation by
delicately balancing MMP and tissue-inhibitor of metal-
loproteinase (TIMP) activity during airway remodeling
[57,70].
Sub-epithelial basement membrane (BM) thickness cor-
relates with asthma severity [71,72]. Severe asthma is
characterized by an increased ASM mass extending from the
trachea to the smallest bronchioles and alveolar ducts
[73e76]. Increases in ASM mass are a key feature of the
airway remodeling process that includes MAPK mediated
thickening of the BM. It is predominantly influenced by
migration of MMPs toward the epithelium to form new
matrix bundles [77]. TGF-ß mediated proliferation of
collagen, fibronectin, serum and platelet-derived growth
factor all play a role and require signaling through RGD
(Arg-Gly-Asp) binding integrins [78]. This leads to stiffer
airways and greater fixed airflow obstruction characteris-
tically seen in severe asthma [79].TGF-ß1 immunosupressive effects and
regulatory inflammatory tolerance
In its role as a pleiotropic and multifunctional growth fac-
tor, TGF-ß1 is a master regulator of immune responses
resulting in fibrosis. As a potent anti-inflammatory, its
chemo-attractive properties cause accumulation of mac-
rophages and granulocytes in local inflammatory sites [80].
Additionally, it promotes development and differentiation
of Th17 and forkheard box P3 (FoxP3) regulatory T-cells
while inducing IL-9-producing T-helper cells [24,81,82].
Regulatory T cells (Treg) are a subpopulation of CD4þ T
cells that maintain immunological self-tolerance and con-
trol the development of autoimmune disease [83]. Treg
cells express the high affinity interleukin-2 (IL-2) receptor
(CD25) and the transcription factor, Foxp3 that play critical
roles in the function and development of Tregs [84]. Two
subtypes of Foxp3þ CD25þ CD4þ Tregs are described: i)
natural Treg (nTreg) from the thymus and ii) acquired/
induced Treg (aTreg/iTreg) that develop peripherally in
response to TGF-b stimulation [84]. Foxp3þ CD25þ CD4þ
Tregs regulate allergy, auto-immunity, transplant rejec-
tion, tumor immunity, and microbial responses [83].
Immunosuppressive Treg effects are mediated by IL-2R
(CD25) and indirectly through antigen presenting cells
(APCs) which in turn are mediated by cytotoxic T-lympho-
cyte-associated protein 4 (CTLA-4) [85,86]. Although
Foxp3þ CD4þ Tregs have suppressive capabilities, CD4
Foxp3 expression alone does not always indicate suppres-
sive consequences. Transient Foxp3 expression in subsets of
TGF-b-induced iTregs do not functionally equate to nTreg
[87,88]. Emerging evidence provide insight into the regu-
latory behavior of Tregs in the context of immune function,
stimulators in certain conditions whilst suppressive in
others largely dependent on the context, location, condi-
tions and target cells in question [89,90].
TGF-b suppresses immune responses through inhibition
of inflammatory cell function and promotion of Tregproduction. TGF-b functions as an inducer for Treg gener-
ation [91]. It converts naive CD25 T cells to regulatory
CD25 þ cells, and additionally regulates Treg suppressive
function [92e94]. Antigens may induce TGF-beproducing
Treg (Th3), which in turn mediates immunosuppression
[95]. Blocking TGF-b in vivo abolishes tolerance and impairs
CD25þFoxp3þ Treg induction; however the precise role of
TGF-b in inducing mucosal Th3 cells is unclear. Evidence
underpinning molecular mechanisms that drive Treg pro-
liferation, activation, survival and targeting will in the
future likely provide potential therapeutic targets in severe
asthma.
By regulation of the homeostasis of lymphocytes and
Tregs, which in turn inhibit Th1 and Th2 responses,
inflammation can be restricted. TGF-ß1 prevents house-
dust mite-induced allergic reactions in murine lungs by
generating CD4þ and CD25þ Treg cells [96]. Administration
of CD4þ and CD25þ Treg cells in an experimental setting
reduces established lung eosinophilia, Th2 infiltration and
promotes expression of IL-5, IL-13 and TGF-ß1 in airway
specimens [97]. TGF-ß1 directly delivered into the trachea
suppresses allergen-induced inflammation suggestive of a
potential therapeutic role [98]. The evidence underlying
the molecular mechanisms driving immunosuppressive Treg
cell proliferation, activation, survival and subsequent tar-
geting however remain to be elucidated.Pro-inflammatory role of TGF-ß1
TGF-ß1 also plays a key role in inflammation acting as a
potent chemotactic factor and activator for a variety of
inflammatory cells. Both inflammatory and structural cells
produce TGF-ß1 contributing to the increased levels
observed in BAL fluid obtained from asthmatic airways
[20,99,100]. Increased TGF-ß1 is associated with higher
macrophage concentrations following allergen challenge
and significantly amplified inflammation through induction
of Th17 cells [42,80,101].
TGF-ß1 airway concentrations have been associated with
airflow limitation in a cross-sectional sample of children
with severe asthma [102]. Increased expression of airway
TGF-ß1 is coupled with an increase in BAL macrophages and
concentrations of lipid peroxidation biomarkers 8-
isoprostanes and malondialdehyde. Oxidative stress may
thus mediate TGF-b1 effects and promote airway remod-
eling in children with severe asthma. Nuclear factor-like 2
(Nrf2) is another factor responsible for regulating gluta-
thione, antioxidant responses and reducing ASM prolifera-
tion in severe asthma [103]. This pathway is also disrupted
in severe asthma due to chronic oxidative stress [104]. TGF-
ß also plays an important role here, suppressing Nrf2 ac-
tivity in ASM cells and consequently promoting a dysregu-
lated antioxidant response [103]. What remains lacking is a
definitive link between elevated airway TGF-ß1 and pro-
gressive loss of pulmonary function from an oxidative
perspective.
Increased expression and activation of airway TGF-ß1
coupled with an increased airway oxidant burden underlies
the physiological alterations accompanying severe asthma
in children. Traffic-related air pollutants and cigarette
smoke cause oxidant mediated airway inflammation and
1414 M. Al-Alawi et al.are also associated with asthma in children [105,106].
Children with the TGF-b 509 TT genotype are at higher
risk of asthma occurrence if they live near a freeway or
were exposed to tobacco smoke in utero [107]. In an
experimental model of rat tracheal explants, two-to three-
fold increases in TGF-b1 expression was observed when the
explants were exposed to urban air particles [108] and
cigarette smoke [109]. Cigarette smoke exposure is known
to enhance antigen-induced mast cell activation via TGF-b/
Smad signaling pathways in a mouse model of allergic
asthma [110]. Kang et al. (2007) demonstrated that ciga-
rette smoking is a potent stimulator of IL-18 release from
pulmonary macrophages [111]. In turn, activated macro-
phages and airway epithelial cells release IL-18 that con-
tributes to the proinflammatory cascade in asthma [112].
For instance, it enhances remodeling through production of
IFN-g, IL-13 and TGF-b1 in an asthma mouse model [113]. In
further animal work, chronic exposure to house dust mite
demonstrated elevated IL-4, IL-13 and TGF-ß1 accompanied
by goblet cell hyperplasia, subepithelial fibrosis and
increased ASM surface area [114]. Taken together this
current evidence suggests that inflammatory and allergic
mechanisms both influence the TGF-ß pathway, and insight
into the effect of cigarette smoking on the induction of
TGF-b1 release from other cells remains to be explored.
Current guidelines for randomized controlled trial
recruitment include recruitment of patients “free” of co-
morbid disease that demonstrate good inhaler technique,
and an asthma diagnosis. Cigarette smoking for example
typically results in patients being excluded from consider-
ation. Consequently, there is exclusion of current and ex-
smokers in addition to patients with at least a ten-pack year
smoking history. Given the foundation of knowledge on the
effects of cigarette smoking on murine models of asthma
[109,110], there is an inherent bias in current trial recruit-
ment preventing the extrapolation of understanding in vivo
TGF-b mediated effects in human asthmatic smokers [115].
Th2 cytokines IL-5 and IL-13 have been intimately linked
to airway TGF-ß1. IL-5 receptor deficient mice have unde-
tectable airway eosinophils and reduced TGF-ß1 concen-
trations concomitant with decreased fibrotic change in a
chronic exposure model [116]. Conversely, IL-5 over-
expression leads to increased eosinophils, TGF-ß, higher
collagen content and more fibrotic consequences. Inhibit-
ing TGF-ß1 signaling specifically in T-cell subsets has led to
enhanced airway inflammation, hypersensitivity and
increased Th2 cytokine production hence its potential
therapeutic role has been controversial [117]. IL-13 induces
TGF-ß1 expression through synergistic mechanisms on
airway processes including remodeling and fibrosis
[64,118]. IL-13 deficient mice have decreased signal trans-
duction, activation of transcription-6 (STAT6) phosphory-
lation and limited TGF-ß1 activity following allergic
stimulation resulting in attenuated bronchial hyper-
responsiveness, ASM hyperplasia, and immunoglobulin-E
(IgE) synthesis [34,119].
An increased quantity and size of goblet cells and
mucosal glands are characteristic of asthma-related airway
obstruction. TGF-ß2 importantly regulates the transcription
and translation of mucin in bronchial epithelial cells [34]
and anti-TGF-ß treatment in animal models of asthma
illustrate a decreased goblet cell burden [120].Expression of VEGF promotes angiogenesis and perme-
ability. Changes to airway microvasculature accompany
airway remodeling and result in VEGF release. TGF-ß1
promotes further microvascular congestion through up-
regulation of pro-angiogenic factors such as VEGF in the
severe asthmatic airway [121]. Interestingly, VEGF inhibi-
tion has been shown to attenuate peribronchial fibrosis
through effects on the phosphoinositide 3-kinase(PI3K)/Akt
pathway [122].
TGF-ß and eosinophil crosstalk
Asthma severity is related to a relationship between TGF-ß
expression and the presence of submucosal eosinophils
[40e42,123]. Minshall et al. examined bronchial biopsies of
severe asthmatics and demonstrated that 65% of TGF-ß1
mRNA-positive cells were eosinophils and that 75% of eo-
sinophils were positive for TGF-ß1 mRNA, findings reflective
of earlier work performed by others [40,42,124]. The study
interestingly also reported strong correlations between
mRNA-positive TGF-ß1 cells beneath the basement mem-
brane and degree of eosinophilia within the same
compartment. The extent of TGF-ß1 expression is signifi-
cantly higher in those with severe compared to mild
asthma. TGF-ß is therefore upregulated in severe asthma
and a strong correlation exists between TGF-ß1 expression,
eosinophil burden and asthma severity.
In the upper airway, eosinophils remain a major source
of TGF-ß in patients with allergic disease. Linear relation-
ships are evident between the degree of eosinophilia and
TGF-ß1 expression in patients with rhinosinusitis [47].
Similar associations are observed with atopic dermatitis
where Th2-predominant infiltration similar to that in
asthma is the major driver of the inflammatory state [125].
Persistent eosinophilia relates to asthma disease
severity and correlates with fixed airflow obstruction,
frequent exacerbations, hospitalizations and increased
intubation rates [15,126,127]. Targeting the eosinophil it-
self has been effective and studies of the anti-IL-5 agent,
mepolizumab illustrates significant reduction in exacerba-
tion rates in corticosteroid dependent patients. In addition,
improved symptom control and quality of life is noted
[128e130]. Flood-Page et al. attempted treatment of pa-
tients with mild atopic asthma with mepolizumab resulting
in decreased tissue eosinophilia, lung TGF-ß1 expression,
reduced remodeling and ECM deposition [41]. Such obser-
vations were further reinforced when IL-5 knockout mice
chronically exposed to allergens showed reductions in the
pulmonary expression of TGF-ß1 [131].
Genetic TGF-ß modifiers
Gene polymorphisms in the TGF-ß1 promoter region are
associated with the development of asthma [9,132]. Several
single nucleotide polymorphisms (SNPs) are associated with
peripheral blood eosinophilia in asthmatic patients [133].
Lerodiakonou et al. (2013) identified asthmatic carriers of
the TGF-ß1 SNP rs6957-G to have significantly higher sub-
mucosal eosinophils and macrophages. In the same study,
the SNPs rs1800469-T and rs1800470-C were associated with
less FEV1 decline and rs4803455-A with accelerated FEV1
Transforming growth factor beta in severe asthma 1415decline. Also of interest, three other SNPs that associated
with increased airflow obstruction (rs6957, rs1800469, and
rs1800470) were also linked to less rapid decline in non-
smokers. Such data provide evidence of critical in-
teractions between TGF-ß1 SNPs and effects of smoking on
asthma severity. Other disease associations link the poly-
morphisms with survival in non-small cell lung cancer [134],
breast cancer [135], and risk of radiation pneumonitis [136].
A recent meta-analysis suggested that the 509/T
polymorphism in TGF-ß1 gene as a risk factor for asthma
susceptibility and phenotype [137,138]. Polymorphism
T869C has also been directly associated to asthma severity
[139e142]. Furthermore, Freimuth et al. importantly
concluded that differential inheritance of genetic loci,
TGFbm, alters biological responses to reduced TGF-ß1
signaling in an experimental asthma model [143]. TGF-ß
antagonists for treatment of lung diseases might therefore
give diverse outcomes among patient cohorts, dependent
on genetic variation. Recent work has also shown that pa-
tients with TGF-ß receptor II mutations were strongly pre-
disposed to the development of multiple immunologic
phenotypes, including asthma, food allergies, eczema,
allergic rhinitis, and eosinophilic gastrointestinal disease
[144]. In LoeyseDeitz syndrome (LDS), a condition with
naturally occurring mutations in this gene, almost half of all
patients had been diagnosed with asthma and increased
eosinophil counts, elevated IgE and increased Th2-
cytokines IL-5 and IL-13. T-cells sequestered from such
patients showed increased Smad 2 and 3 phosphorylation in
response to TGF-ß1 that in turn enhanced its signaling.
Angiotensin-II receptor blockade (e.g. losartan) interest-
ingly mitigates TGF-ß signaling in lymphocytes of LDS pa-
tients suggesting that this or other related treatment
approaches hold promise in the prevention of major car-
diovascular complications and perhaps the development of
asthma if administered at an early stage [145,146]. Future
work should re-visit the previously demonstrated interac-
tion between blocking the renin-angiotensin system and
effects on TGF-ß1 signaling in asthma.TGF-ß targeted therapy
Current therapeutic guidelines for the treatment of asthma
are ineffective at targeting any reversal of the airway
structural remodeling process. Corticosteroids however
have been shown to exhibit an inhibitory effect on TGF-ß1
expression in a murine model of asthma hence illustrating
some albeit minimal potential in affecting this irreversible
process [147]. In humans however, a two-week course of
oral corticosteroids did not inhibit TGF-ß production and
was deemed ineffective at modulating the fibrotic process
[101]. Although these findings validate other studies
demonstrating minimal effects of corticosteroids on the
airway remodeling process, recent evidence identifies
novel mechanistic effects of glucocorticoids on TGF-b
signaling cross talk [148]. Glucocorticoids recruited the
accessory TGF-b receptor, Tgfbr3, and Smad-1 to shift TGF-
b signaling from the Tgfbr1/Smad2/3 axis to an Acvrl1/
Smad1 axis in lung fibroblasts. Such findings illustrate the
importance of glucocorticoids on the array of TGF-b medi-
ated responses in inflammatory airway diseases.In-vitro and -vivo evidence suggests a role for activin A, a
promising target in regulating the inflammatory fibrotic
remodeling process within the airway [149,150]. It is a
member of the TGF-b superfamily through which inhibition,
by follistatin, decreases mucus hypersecretion, sub-
epithelial collagen deposition and thickening of the sub-
epithelial smooth muscle, indicating a potential therapeutic
role in the prevention of airway remodeling [151].
Tiotropium bromide reduced levels of TGF-ß1 in BAL of
OVA-sensitized mice. In addition, it abrogated airway
hyper-responsiveness to serotonin and inhibited Th2 cyto-
kine production [152]. Such inhibitory effects on acute
versus chronic asthma are dependent on differential
expression of muscarinic receptor subtypes [153]. Evidence
by Schaafsma et al. highlights that simvastatin may inhibit
TGF-b1-induced fibronectin expression in airway fibroblasts
[154] which in turn attenuates fibroblast-to-myofibroblast
transition in asthmatic settings [155].
Targeting TGF-ß represents a major challenge as a target
for severe asthma therapy. The complexity of its signaling
network has thus far hindered the pursuit of specific drug
candidates targeting TGF-ß. Neutralizing antibodies that
block TGF-ß activity through phosho-Smad 2 appear at least
in preliminary animal work to prevent lung fibrosis in
asthma [156,157]. SD-208 has been trialed as a TGF-bRI
kinase inhibitor in a chronic rat allergic asthma model
[158]. Effects include inhibiting all TGF-b isoforms, bron-
chial and ASM cell proliferation and goblet cell hyperplasia
all induced by exposure to allergens.
The effects of TGF-ß1 on airway remodeling are variable
and largely depend on the local environment and model
used for investigation [47]. The therapeutic treatment of
mice with anti-TGF-ß antibodies significantly reduced pul-
monary peri-bronchiolar ECM deposition, ASM proliferation,
and mucus production without affecting established airway
inflammation and Th2 cytokine production. These data
suggest therefore that inflammation and remodeling may be
uncoupled during a prolonged allergic challenge [120].
Chronic exposure to HDM demonstrated elevated IL-4, IL-13
and TGF-ß1 levels accompanied by goblet cell hyperplasia,
subepithelial fibrosis and increased ASM surface area [114].
Difficulties however arise as contrasting evidence has shown
that anti-TGF-b treatment in the context of continuous or
intermittent HDM exposure had no effect on the develop-
ment of HDM-induced airway remodeling. TGF-ß neutrali-
zation in fact exacerbated eosinophilic infiltrates and led to
increased airway hyper-responsiveness in some cases [159].
These findings may in part be explained by the differential
expression of TGF-b isoforms in response to duration of HDM
exposure [35]. Taken together, this work suggests that we
remain unclear as to the true benefits of targeting the TGF-b
pathway and need to be fairly specific during the process to
ensure beneficial as opposed to adverse effects.
Anti-TGF-ß1 antibodies have been demonstrated to
inhibit monocyte/macrophage recruitment and reduce
eosinophil and lymphocyte numbers within the airway [19].
Treatment with mepacrine, a synthetic anti-malarial drug
reduces TGF-ß1 and subsequently sub-epithelial airway
fibrosis [160]. The cytokine IFN-g has been shown to
downregulate TGF-ß2 through Smad-7, however their
therapeutic consequences in the asthmatic airway remain
undetermined [161].
Figure 2 Multifunctional role of TGF-b in severe asthma. TGF, produced mainly by eosinophils in the asthmatic airway exerts
multiple effects that influence inflammation and airway remodeling. (EMT: Epithelial-mesenchymal transition, ECM: Extracellular
matrix, MAPK:p38-mitogen-activated protein kinase, Nrf2: Nuclear factor-like2, Th1/2: T helper cells 1/2, Treg: Regulatory T cells,
IL: Interleukin). (Blue arrow indicates activation, red line indicates inhibition). (For interpretation of the references to color in
this figure legend, the reader is referred to the web version of this article.)
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inflammation, cell migration, and tissue remodeling in
asthmatic airways has important pathophysiological and
clinical consequences that must be recognized in the
context of emerging asthma therapeutics that target Th2-
driven inflammation [162]. Use of antisense oligonucleotide
therapy against TGF-ß has been applied in animal models in
an attempt to reduce postoperative scarring in ocular
glaucoma [163]. Similarly, adenoviral delivery to over-
express Smad-2 within the lung results surprisingly in an
increased sub-epithelial collagen deposition and ASM hy-
perplasia. These effects lead to thickening of the ASM layer
following HDM challenge [164] (Fig. 2). In view of con-
trasting outcomes to anti-TGF-b approaches particularly in
the context of allergy and asthma, future work focused on
the complex signaling network involved will be necessary
before we can progress to valid clinical study.
Conclusion and future directions
Suboptimal patient selection for certain asthmatic clinical
studies may at least partially account for the contrasting
pool of evidence with regards differences in TGF-ß1
immunohistochemical staining between asthmatics and
healthy controls [32,165,166]. This is further complicated
by our emerging understanding of the various clinical phe-
notypes within the asthma spectrum. Airway TGF-ß1
release is inducible and transient however does require an
inflammatory or antigenic challenge [47]. Effectivemodulation of TGF-ß is therefore dependent on prolifera-
tive factors that induce its transient release in asthma
subsequently regulating ASM thickness [167e169]. Con-
trasting effects of TGF-b may be due to differences in cell
origin (airway versus alveolar, transformed versus primary
and human versus rodent), differences in matrix or integrin
expression, or concentration-dependent responses [56].
Latent TGF-ß activation and isoform differentiation further
complicates the asthmatic setting and adds to the
complexity of its role in the diseased airway. Stored in large
quantities within the airway ECM, it plays major roles in
regulating inflammation and its consequences.
While down regulating the inflammatory process through
the induction of immunosuppressive Tregs, it also initiates
structural remodeling. A delicate balance between such
phenomena defines the precise role for TGF-ß in the clin-
icopathophysiologic phenotypes observed in severe asthma.
TGF-ß modulation is potentially useful in immunosuppres-
sion while pure global inhibition may have anti-fibrotic ef-
fects. Development of targeted TGF-ß therapy will likely
need to be individualized specifically to the phenotypic
spectrum of patients with severe asthma where immuno-
suppression may be desirable if it is to become a successful
component in future asthma care.
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